Filtered By:
Source: European Heart Journal
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 120 results found since Jan 2013.

Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry
Conclusion Left atrial appendage closure with the WATCHMAN device has a high success rate in complete LAAC with low peri-procedural risk, even in a population with a higher risk of stroke and bleeding, and multiple co-morbidities. Improvement in implantation techniques has led to a reduction of peri-procedural complications previously limiting the net clinical benefit of the procedure.
Source: European Heart Journal - August 23, 2016 Category: Cardiology Authors: Boersma, L. V. A., Schmidt, B., Betts, T. R., Sievert, H., Tamburino, C., Teiger, E., Pokushalov, E., Kische, S., Schmitz, T., Stein, K. M., Bergmann, M. W., on behalf of the EWOLUTION investigators, Nooryani, Meincke, Mobius-Winkler, Senatore, Foley, Sch Tags: Atrial fibrillation Source Type: research

Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries
Conclusion Ablation may be associated with lower incidence of ischaemic stroke and death in patients with AF. This beneficial finding appears more pronounced in patients with higher thromboembolic risk.
Source: European Heart Journal - August 23, 2016 Category: Cardiology Authors: Friberg, L., Tabrizi, F., Englund, A. Tags: Arrhythmia/electrophysiology Source Type: research

Does catheter ablation reduce mortality and stroke in patients with atrial fibrillation? Patient selection or causality?
Source: European Heart Journal - August 23, 2016 Category: Cardiology Authors: Nielsen, J. C., Gerdes, J. C. Tags: Editorial Source Type: research

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
AbstractIn 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace 2013;15:625 –651; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in...
Source: European Heart Journal - June 9, 2016 Category: Cardiology Source Type: research

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
Conclusion A novel biomarker-based risk score for predicting stroke in AF was successfully developed and internally validated in a large cohort of patients with AF and further externally validated in an independent AF cohort. The ABC-stroke score performed better than the presently used clinically based risk score and may provide improved decision support in AF. ClinicalTrials. gov identifier NCT00412984, NCT00799903.
Source: European Heart Journal - May 20, 2016 Category: Cardiology Authors: Hijazi, Z., Lindback, J., Alexander, J. H., Hanna, M., Held, C., Hylek, E. M., Lopes, R. D., Oldgren, J., Siegbahn, A., Stewart, R. A. H., White, H. D., Granger, C. B., Wallentin, L., the ARISTOTLE and STABILITY Investigators Tags: Atrial fibrillation Source Type: research

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Conclusion XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number Clinicaltrials.gov: NCT01606995.
Source: European Heart Journal - April 6, 2016 Category: Cardiology Authors: Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., van Eickels, M., Turpie, A. G. G., the XANTUS Investigators Tags: Atrial fibrillation Source Type: research

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation
Conclusion</strong> Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.</span>
Source: European Heart Journal - February 29, 2016 Category: Cardiology Source Type: research

CardioPulse Articles * Gerhard Hindricks MD * Cardiac Centres Of Excellence * Leipzig Heart Centre - Department of Electrophysiology * New perspectives for stroke prevention in atrial fibrillation * Syncope and near drowning may signal sudden death risk * Ear stimulation for atrial fibrillation favoured at ESC Congress London
Source: European Heart Journal - February 14, 2016 Category: Cardiology Tags: CardioPulse Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
<span class="paragraphSection">Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a particular pattern of risk factors and concomitant diseases. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. NOA...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
<span class="paragraphSection">The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non-vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two-part review, we discuss the use of NOAC for stroke prevent...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
Conclusion In the ARISTOTLE trial, women had a similar rate of stroke or systemic embolism but a lower risk of mortality and less clinically relevant bleeding than men. The efficacy and safety benefits of apixaban compared with warfarin were consistent in men and women. Trial registration ARISTOTLE ClinicalTrials.gov number, NCT00412984.
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: Vinereanu, D., Stevens, S. R., Alexander, J. H., Al-Khatib, S. M., Avezum, A., Bahit, M. C., Granger, C. B., Lopes, R. D., Halvorsen, S., Hanna, M., Husted, S., Hylek, E. M., Mărgulescu, A. D., Wallentin, L., Atar, D. Tags: Atrial fibrillation Source Type: research

Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study
Conclusion Both in the overall population as well as in the angina subset, bradycardia was common in ivabradine-treated patients, but did not appear to impact outcomes. Emergent AF was relatively rare and did not appear to have an impact on outcomes relative to placebo. Clinical trials registration ISRCTN61576291
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: Fox, K., Ford, I., Steg, P. G., Tardif, J.-C., Tendera, M., Ferrari, R., the SIGNIFY investigators Tags: Coronary artery disease Source Type: research

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
Conclusions The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: O'Brien, E. C., Simon, D. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., Kowey, P. R., Mahaffey, K. W., Chang, P., Fonarow, G. C., Pencina, M. J., Piccini, J. P., Peterson, E. D. Tags: Atrial fibrillation Source Type: research

CardioPulse Articles * The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases * 'Ten Commandments' of 2015 ESC Guidelines for diagnosis and management of pericardial diseases * The Russian National Congress of Cardiology 2015 * Germany's largest heart centre * Professor Christoph Bode * Professor Franz-Josef Neumann * The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history
Source: European Heart Journal - November 7, 2015 Category: Cardiology Tags: CardioPulse Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research